High-Dose PPI Plus Aspirin Reduced Esophageal Cancer Risk


Combination therapy with a high-dose proton pump inhibitor and aspirin reduced the risk of progression to esophageal cancer in patients with Barrett esophagus.

The combined use of aspirin and a high-dose proton pump inhibitor (PPI) appears to offer protection against the development of esophageal cancer in high-risk individuals, according to new findings presented at the 2018 American Society of Clinical Oncology Annual Meeting (abstract LBA4008). This strategy reduced the risk of developing high-grade dysplasia or progression to malignancy, and delayed death from any cause in people with Barrett esophagus. 

Lead study author Janusz Jankowski, MD, PhD, Deputy Vice Chancellor, Royal College of Surgeons, Ireland and Consultant Clinical Adviser, National Institutes for Health and Care Excellence, UK, estimated that these outcomes could be delayed by using these simple, over-the-counter products. While esophageal cancer is relatively uncommon, it is challenging to treat and has a very poor prognosis, with a 5-year survival rate of about 19%. Esomeprazole given at 40 mg twice daily, combined with low-dose aspirin, was the most effective of four chemoprevention strategies investigated in this randomized trial.

However, while individuals suffering from heartburn should discuss their risk of Barrett esophagus with their doctor, they “should not self-medicate with these medications,” Jankowski said.

Jankowski noted that the magnitude of the overall benefits observed in their trial were somewhat surprising and greater than expected.

“More than 52,000 cases of esophageal adenocarcinoma occur each year, with 5-year survival less than 10%,” he said. “The increasing incidence of esophageal adenocarcinoma is probably related to the rise in gastroesophageal reflux, Barrett esophagus, and the associated inflammation.”

PPIs reduce acid reflux and aspirin reduces inflammation, so both may have chemopreventive properties, he noted.

Jankowski also pointed out that the United Kingdom has one of the highest rates of esophageal cancer in the world. He further added that “there’s nowhere in the world that’s got more esophageal adenocarcinoma than my home city of Glasgow. In fact, the cancer prognosis for people hasn’t achieved much improvement in 30 or 40 years.”

The phase III ASPECT study included 2,563 individuals who had ≥ 1 cm of Barrett esophagus at baseline and were negative for high-grade dysplasia or esophageal adenocarcinoma. Participants were randomized to one of four study groups: high-dose esomeprazole (80-mg daily), high-dose esomeprazole (300-mg daily) with low-dose aspirin, low-dose esomeprazole (40-mg daily), or low-dose esomeprazole with low-dose aspirin. The primary endpoint was time to death from any cause, diagnosis of esophageal cancer, or diagnosis of high-grade dysplasia (precancer) (three combined events), and the analysis was adjusted for patient age and duration of Barrett esophagus.

The median follow-up was 8.9 years, and the investigators found that high-dose esomeprazole had a statistically significant benefit on the combined endpoint compared with standard-dose esomeprazole (P = .0459). The most effective regimen was high-dose esomeprazole with low-dose aspirin.

The 8-year survival rates were 90% vs 87% patients treated with for high-dose vs low-dose esomeprazole (P = .0459). However, this survival benefit was not observed until 7 years into the protocol.

There was no benefit to aspirin when compared with no aspirin in the primary analysis, but there was a weak effect when censored for prior NSAID use. Overall the treatment regimens were safe, with serious side effects reported in only 1% of patients.

Commenting on the study, Andrew Epstein, MD, an ASCO Expert from Memorial Sloan Cancer Center in New York City, agreed that “patients with Barrett esophagus should speak with their physicians” about using this combination to delay and/or mitigate progression to cancer. But he also emphasized that these recommendations do not apply to everyone with gastroesophageal reflux.

“I want to stress that these are patients with Barrett’s, and we have to be very careful not to extrapolate to other settings, such as patients with symptoms of reflux but without a diagnosis of Barrett’s,” he said.



Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content